1 / 24

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting. PD-1/ PD-L1 pathway in suppressing anti-tumor immunity .

kort
Download Presentation

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  2. PD-1/ PD-L1 pathway in suppressing anti-tumor immunity Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  3. Slide 3 Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  4. Nivolumab <br />(ONO4538/BMS936558) Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  5. Study design: Investigator initiated, 2 cohorts Phase II Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  6. Key inclusion criteria Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  7. Study schedule Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  8. Demographics Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  9. Adverse events: Regardless of causality <br /> (>=4 patients) Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  10. Slide 10 Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  11. Serious adverse events<br />(Treatment-related) Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  12. Clinical Effect : Best Overall Response Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  13. A Responder with Serous adenoca : <br />Nivolumab 3mg/kg Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  14. A Responder with Clear cell carcinoma :<br />Nivolumab 3mg/kg Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  15. Best overall responses in all patients Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  16. Best overall responses in all patients in 2 cohorts Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  17. Summary Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  18. Conclusions Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  19. Acknowledgements Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  20. Research group Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  21. Slide 21 Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  22. Clinical Effect : Response Duration Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  23. Best overall responses in all patients Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

  24. Slide 24 Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

More Related